Fig. 3From: Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer1000 Monte Carlo simulation diagram of pembrolizumab versus chemotherapy in the probabilistic sensitivity analysis. ICE, incremental cost-effectivenessBack to article page